Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHAR Stock Forecast 2025-2026
$16.75
Current Price
$1.15B
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHAR Price Targets
+150.7%
To High Target of $42.00
+120.9%
To Median Target of $37.00
-16.4%
To Low Target of $14.00
PHAR Price Momentum
+3.3%
1 Week Change
+8.6%
1 Month Change
+102.8%
1 Year Change
+66.5%
Year-to-Date Change
-6.2%
From 52W High of $17.86
+123.3%
From 52W Low of $7.50
📊 TOP ANALYST CALLS
Did PHAR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pharming is one of their latest high-conviction picks.
Latest PHAR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PHAR has a bullish consensus with a median price target of $37.00 (ranging from $14.00 to $42.00). The overall analyst rating is N/A (N/A/10). Currently trading at $16.75, the median forecast implies a 120.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Lucy Codrington at Jefferies, suggesting a 16.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHAR Analyst Ratings
3
Buy
0
Hold
0
Sell
PHAR Price Target Range
Low
$14.00
Average
$37.00
High
$42.00
Current: $16.75
Latest PHAR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHAR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 14, 2025 | Oppenheimer | Michael Carrier | Outperform | Maintains | $39.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Dec 9, 2024 | Jefferies | Lucy Codrington | Buy | Initiates | $14.00 |
| Oct 28, 2024 | Oppenheimer | Michael Carrier | Outperform | Maintains | $30.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Oct 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| May 31, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Aug 3, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Mar 28, 2023 | Oppenheimer | Michael Carrier | Outperform | Maintains | $40.00 |
| Mar 27, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
| Feb 22, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $37.00 |
Pharming Group N.V. - ADR (PHAR) Competitors
The following stocks are similar to Pharming based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharming Group N.V. - ADR (PHAR) Financial Data
Pharming Group N.V. - ADR has a market capitalization of $1.15B with a P/E ratio of 69.3x. The company generates $362.27M in trailing twelve-month revenue with a 0.1% profit margin.
Revenue growth is +30.0% quarter-over-quarter, while maintaining an operating margin of +26.6% and return on equity of +0.0%.
Valuation Metrics
Market Cap
$1.15B
Enterprise Value
$8.38B
P/E Ratio
69.3x
PEG Ratio
N/A
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
+30.0%
Gross Margin
+92.7%
Operating Margin
+26.6%
Net Margin
+0.1%
EPS Growth
+30.0%
Financial Health
Cash/Price Ratio
+2.0%
Current Ratio
3.2x
Debt/Equity
49.5x
ROE
+0.0%
ROA
+5.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pharming Group N.V. - ADR (PHAR) Business Model
About Pharming Group N.V. - ADR
What They Do
Develops therapeutic proteins for rare diseases.
Business Model
Pharming Group N.V. operates by developing and commercializing therapeutic proteins, particularly focusing on rare diseases. The company generates revenue primarily through its flagship product, RUCONEST®, which treats hereditary angioedema. Its innovative production platform uses transgenic rabbits to create high-quality proteins, enhancing its ability to address unmet medical needs.
Additional Information
As an American Depositary Receipt (ADR), Pharming Group N.V. offers U.S. investors a way to invest in its biopharmaceutical innovations while diversifying their portfolios. The company's unique approach to protein production positions it strategically within the healthcare sector, contributing significantly to advancements in medical therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
404
CEO
Mr. Fabrice Chouraqui Ph.D., Pharm.D.
Country
Netherlands
IPO Year
2020
Website
www.pharming.comPharming Group N.V. - ADR (PHAR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade
The mean of analysts' price targets for Pharming Group (PHAR) points to an 81.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nov 26, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade
12 days ago
Quick Summary
Analysts' price targets for Pharming Group (PHAR) suggest an 81.7% upside. Consensus in raised earnings estimates signals potential stock growth.
Why It Matters
Analysts' price targets suggest significant upside for Pharming Group, and consensus on raised earnings estimates signals potential growth, influencing investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Pharming Group N.V. (PHAR) shares are rising, supported by positive earnings estimate revisions, suggesting potential continued upward momentum.
Why It Matters
Rising earnings estimate revisions for Pharming Group suggest potential for share price appreciation, signaling positive market sentiment and growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect?
28 days ago
Quick Summary
Analysts' price targets for Pharming Group (PHAR) suggest a 100.9% upside. Consensus among analysts on increased earnings estimates indicates potential stock growth.
Why It Matters
Analysts' price targets suggesting a 100.9% upside for Pharming Group, along with rising earnings estimates, signals potential growth and heightened investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Pharming Group N.V. (PHAR) will hold its Q3 2025 earnings call on November 6, 2025, at 7:30 AM EST, featuring key executives and analysts from various firms.
Why It Matters
Pharming Group's Q3 earnings call provides insights into their financial performance and strategic direction, crucial for assessing future growth and investment potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
1 month ago
Quick Summary
Pharming Group N.V. will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025.
Why It Matters
Pharming's participation in a major healthcare conference could signal potential investor interest, updates on developments, or partnerships, impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
1 month ago
Quick Summary
Pharming will report its Q3 2025 financial results and provide a business update on November 6, 2025, with a conference call at 13:30 CET/07:30 ET.
Why It Matters
Pharming's upcoming Q3 2025 financial results and business update could influence stock performance and investor sentiment based on growth, profitability, and strategic direction.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHAR Stock
What is Pharming Group N.V. - ADR's (PHAR) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Pharming Group N.V. - ADR (PHAR) has a median price target of $37.00. The highest price target is $42.00 and the lowest is $14.00.
Is PHAR stock a good investment in 2026?
According to current analyst ratings, PHAR has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHAR stock?
Wall Street analysts predict PHAR stock could reach $37.00 in the next 12 months. This represents a 120.9% increase from the current price of $16.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pharming Group N.V. - ADR's business model?
Pharming Group N.V. operates by developing and commercializing therapeutic proteins, particularly focusing on rare diseases. The company generates revenue primarily through its flagship product, RUCONEST®, which treats hereditary angioedema. Its innovative production platform uses transgenic rabbits to create high-quality proteins, enhancing its ability to address unmet medical needs.
What is the highest forecasted price for PHAR Pharming Group N.V. - ADR?
The highest price target for PHAR is $42.00 from at , which represents a 150.7% increase from the current price of $16.75.
What is the lowest forecasted price for PHAR Pharming Group N.V. - ADR?
The lowest price target for PHAR is $14.00 from Lucy Codrington at Jefferies, which represents a -16.4% decrease from the current price of $16.75.
What is the overall PHAR consensus from analysts for Pharming Group N.V. - ADR?
The overall analyst consensus for PHAR is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are PHAR stock price projections?
Stock price projections, including those for Pharming Group N.V. - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 4:34 PM UTC